Literature DB >> 21837488

[Renal cell carcinoma].

P Fornara1, M R Hoda.   

Abstract

Approximately 85% of all malignant tumors of the kidney are renal cell carcinomas (RCC). Sonography is the leading examination for early detection of kidney tumors. The treatment of RCC has been enriched in recent years by new therapeutic options for localized and metastatic cancer. The classification of RCC is based on TNM and UICC criteria. The so-called Motzer criteria are being increasingly employed to assess prognosis and monitor therapy and as the basis for reaching decisions on choosing the type of systemic treatment.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21837488     DOI： 10.1007/s00120-011-2677-5

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  17 in total

Review 1.  Clinical practice. Small renal mass.

Authors:  Inderbir S Gill; Monish Aron; Debra A Gervais; Michael A S Jewett
Journal:  N Engl J Med       Date:  2010-02-18       Impact factor: 91.245

Review 2.  Renal-cell carcinoma.

Authors:  Herbert T Cohen; Francis J McGovern
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

3.  Positive margins in laparoscopic partial nephrectomy in 855 cases: a multi-institutional survey from the United States and Europe.

Authors:  A Breda; S V Stepanian; J Liao; J S Lam; G Guazzoni; M Stifelman; K Perry; A Celia; G Breda; P Fornara; S Jackman; A Rosales; J Palou; M Grasso; V Pansadoro; V Disanto; F Porpiglia; C Milani; C Abbou; R Gaston; G Janetschek; N A Soomro; J de la Rosette; M P Laguna; P G Schulam
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

4.  The future of nephron sparing procedures for renal masses: balancing costs, efficacy, patient outcomes and experience.

Authors:  Yair Lotan
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

5.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

6.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

7.  Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881.

Authors:  Jan H M Blom; Hein van Poppel; Jean M Maréchal; Didier Jacqmin; Fritz H Schröder; Linda de Prijck; Richard Sylvester
Journal:  Eur Urol       Date:  2008-10-01       Impact factor: 20.096

8.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

Review 9.  Surgical management of localised renal cell carcinoma.

Authors:  Ghulam Nabi; Anne Cleves; Mike Shelley
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

Review 10.  Targeted therapy for advanced renal cell carcinoma.

Authors:  C Coppin; L Le; F Porzsolt; T Wilt
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16
View more
  2 in total

1.  Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway.

Authors:  Sascha D Markowitsch; Olesya Vakhrusheva; Patricia Schupp; Yasminn Akele; Jovana Kitanovic; Kimberly S Slade; Thomas Efferth; Anita Thomas; Igor Tsaur; René Mager; Axel Haferkamp; Eva Juengel
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

2.  Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis.

Authors:  Anja Rabien; Carsten Stephan; Ergin Kilic; Wilko Weichert; Glen Kristiansen; Kurt Miller; Klaus Jung; Andreas Erbersdobler
Journal:  J Transl Med       Date:  2013-10-16       Impact factor: 5.531
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.